Table 1 Characteristics of Patients Who Developed SPMs After CAR-T Therapy
From: Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Characteristics | N = 21 (%) |
|---|---|
Age at CAR-T (in years), median (range) | 66 (28–76) |
Number of lines of therapy prior to CAR-T, median (range) | 4 (2–23) |
Sex | |
Male | 14 (67) |
Female | 7 (33) |
Disease type | |
LBCL* | 14 (67) |
SLL/CLL transformed to DLBCL** | 2 (10) |
MCL | 2 (10) |
MM | 2 (10) |
PMBCL | 1 (5) |
Prior HSCT | 8 (38) |
LD chemotherapy | |
Fludarabine + Cyclophosphamide | 21 (100) |
CAR-T product | |
Axicabtagene ciloleucel | 12 (57) |
Tisagenlecleucel | 4 (19) |
Idecabtagene vicleucel | 2 (10) |
Brexucabtagene autoleucel | 2 (10) |
Lisocabtagene maraleucel | 1 (5) |